Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

M. Gentile, T.D. Shanafelt, F.R. Mauro, G. Reda, D. Rossi, L. Laurenti, M.I. Del Principe, G. Cutrona, I. Angeletti, M. Coscia, Y. Herishanu, A. Chiarenza, S. Molica, S. Ciolli, N. Goldschmidt, F. Angrilli, A. Giordano, A. Rago, O. Bairey, G. TripepiK.G. Chaffee, P.A. Sameer, E. Vigna, K. Zirlik, L. Shvidel, I. Innocenti, A.G. Recchia, F. Di Raimondo, G. Del Poeta, A. Cortelezzi, A. Neri, M. Ferrarini, G. Gaidano, N.E. Kay, A. Polliack, R. Foà, F. Morabito

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)703-706
Number of pages4
JournalEuropean Journal of Haematology
Issue number5
Publication statusPublished - 2018


  • bendamustine
  • cyclophosphamide
  • fludarabine
  • ofatumumab
  • pentostatin
  • protein p53
  • rituximab, adult
  • aged
  • cancer combination chemotherapy
  • cancer immunotherapy
  • cancer patient
  • cancer prognosis
  • cancer risk
  • cancer survival
  • chronic lymphatic leukemia
  • Chronic Lymphocytic Leukemia International Prognostic Index
  • clinical feature
  • cohort analysis
  • female
  • follow up
  • gene mutation
  • high risk patient
  • human
  • intermediate risk patient
  • International Prognostic Index
  • Letter
  • leukemogenesis
  • low risk patient
  • major clinical study
  • male
  • overall survival
  • predictive value
  • priority journal
  • progression free survival
  • validation study

Cite this

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. / Gentile, M.; Shanafelt, T.D.; Mauro, F.R.; Reda, G.; Rossi, D.; Laurenti, L.; Del Principe, M.I.; Cutrona, G.; Angeletti, I.; Coscia, M.; Herishanu, Y.; Chiarenza, A.; Molica, S.; Ciolli, S.; Goldschmidt, N.; Angrilli, F.; Giordano, A.; Rago, A.; Bairey, O.; Tripepi, G.; Chaffee, K.G.; Sameer, P.A.; Vigna, E.; Zirlik, K.; Shvidel, L.; Innocenti, I.; Recchia, A.G.; Di Raimondo, F.; Del Poeta, G.; Cortelezzi, A.; Neri, A.; Ferrarini, M.; Gaidano, G.; Kay, N.E.; Polliack, A.; Foà, R.; Morabito, F.

In: European Journal of Haematology, Vol. 101, No. 5, 2018, p. 703-706.

Research output: Contribution to journalArticle

Gentile, M, Shanafelt, TD, Mauro, FR, Reda, G, Rossi, D, Laurenti, L, Del Principe, MI, Cutrona, G, Angeletti, I, Coscia, M, Herishanu, Y, Chiarenza, A, Molica, S, Ciolli, S, Goldschmidt, N, Angrilli, F, Giordano, A, Rago, A, Bairey, O, Tripepi, G, Chaffee, KG, Sameer, PA, Vigna, E, Zirlik, K, Shvidel, L, Innocenti, I, Recchia, AG, Di Raimondo, F, Del Poeta, G, Cortelezzi, A, Neri, A, Ferrarini, M, Gaidano, G, Kay, NE, Polliack, A, Foà, R & Morabito, F 2018, 'Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment', European Journal of Haematology, vol. 101, no. 5, pp. 703-706.
Gentile, M. ; Shanafelt, T.D. ; Mauro, F.R. ; Reda, G. ; Rossi, D. ; Laurenti, L. ; Del Principe, M.I. ; Cutrona, G. ; Angeletti, I. ; Coscia, M. ; Herishanu, Y. ; Chiarenza, A. ; Molica, S. ; Ciolli, S. ; Goldschmidt, N. ; Angrilli, F. ; Giordano, A. ; Rago, A. ; Bairey, O. ; Tripepi, G. ; Chaffee, K.G. ; Sameer, P.A. ; Vigna, E. ; Zirlik, K. ; Shvidel, L. ; Innocenti, I. ; Recchia, A.G. ; Di Raimondo, F. ; Del Poeta, G. ; Cortelezzi, A. ; Neri, A. ; Ferrarini, M. ; Gaidano, G. ; Kay, N.E. ; Polliack, A. ; Foà, R. ; Morabito, F. / Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. In: European Journal of Haematology. 2018 ; Vol. 101, No. 5. pp. 703-706.
title = "Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment",
keywords = "bendamustine, cyclophosphamide, fludarabine, ofatumumab, pentostatin, protein p53, rituximab, adult, aged, cancer combination chemotherapy, cancer immunotherapy, cancer patient, cancer prognosis, cancer risk, cancer survival, chronic lymphatic leukemia, Chronic Lymphocytic Leukemia International Prognostic Index, clinical feature, cohort analysis, female, follow up, gene mutation, high risk patient, human, intermediate risk patient, International Prognostic Index, Letter, leukemogenesis, low risk patient, major clinical study, male, overall survival, predictive value, priority journal, progression free survival, validation study",
author = "M. Gentile and T.D. Shanafelt and F.R. Mauro and G. Reda and D. Rossi and L. Laurenti and {Del Principe}, M.I. and G. Cutrona and I. Angeletti and M. Coscia and Y. Herishanu and A. Chiarenza and S. Molica and S. Ciolli and N. Goldschmidt and F. Angrilli and A. Giordano and A. Rago and O. Bairey and G. Tripepi and K.G. Chaffee and P.A. Sameer and E. Vigna and K. Zirlik and L. Shvidel and I. Innocenti and A.G. Recchia and {Di Raimondo}, F. and {Del Poeta}, G. and A. Cortelezzi and A. Neri and M. Ferrarini and G. Gaidano and N.E. Kay and A. Polliack and R. Fo{\`a} and F. Morabito",
note = "cited By 0",
year = "2018",
doi = "10.1111/ejh.13149",
language = "English",
volume = "101",
pages = "703--706",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",



T1 - Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

AU - Gentile, M.

AU - Shanafelt, T.D.

AU - Mauro, F.R.

AU - Reda, G.

AU - Rossi, D.

AU - Laurenti, L.

AU - Del Principe, M.I.

AU - Cutrona, G.

AU - Angeletti, I.

AU - Coscia, M.

AU - Herishanu, Y.

AU - Chiarenza, A.

AU - Molica, S.

AU - Ciolli, S.

AU - Goldschmidt, N.

AU - Angrilli, F.

AU - Giordano, A.

AU - Rago, A.

AU - Bairey, O.

AU - Tripepi, G.

AU - Chaffee, K.G.

AU - Sameer, P.A.

AU - Vigna, E.

AU - Zirlik, K.

AU - Shvidel, L.

AU - Innocenti, I.

AU - Recchia, A.G.

AU - Di Raimondo, F.

AU - Del Poeta, G.

AU - Cortelezzi, A.

AU - Neri, A.

AU - Ferrarini, M.

AU - Gaidano, G.

AU - Kay, N.E.

AU - Polliack, A.

AU - Foà, R.

AU - Morabito, F.

N1 - cited By 0

PY - 2018

Y1 - 2018

KW - bendamustine

KW - cyclophosphamide

KW - fludarabine

KW - ofatumumab

KW - pentostatin

KW - protein p53

KW - rituximab, adult

KW - aged

KW - cancer combination chemotherapy

KW - cancer immunotherapy

KW - cancer patient

KW - cancer prognosis

KW - cancer risk

KW - cancer survival

KW - chronic lymphatic leukemia

KW - Chronic Lymphocytic Leukemia International Prognostic Index

KW - clinical feature

KW - cohort analysis

KW - female

KW - follow up

KW - gene mutation

KW - high risk patient

KW - human

KW - intermediate risk patient

KW - International Prognostic Index

KW - Letter

KW - leukemogenesis

KW - low risk patient

KW - major clinical study

KW - male

KW - overall survival

KW - predictive value

KW - priority journal

KW - progression free survival

KW - validation study

U2 - 10.1111/ejh.13149

DO - 10.1111/ejh.13149

M3 - Article

VL - 101

SP - 703

EP - 706

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 5

ER -